Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 209
Filter
1.
Rhinology ; 58(2): 136-144, 2020 Apr 01.
Article in English | MEDLINE | ID: mdl-31904030

ABSTRACT

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease, and its pathogenesis remains controversial. This study aimed to examine the involvement of fungi in CRSwNP pathogenesis. METHODS: We enrolled 29 controls and 111 CRSwNP patients. We analyzed fungi in the nasal secretions, serum fungus-specific immunoglobulin E (IgE) levels, and nasal polyp (NP) IgE levels. Moreover, we evaluated the correlation between patients' IgE levels and computed tomography (CT) scores. RESULTS: There was no difference in fungal detection rate between CRSwNP patients with and without asthma. Specific IgEs against various antigens were highly detectable in NPs of CRSwNP patients. In CRSwNP patients, fungus-specific IgE levels in NPs were correlated with CT scores. Serum fungus-specific IgEs became undetectable after operation in more than half of the CRSwNP patients without asthma but not in those with asthma. Other serum airborne antigen-specific IgEs did not become undetectable after operation. CONCLUSIONS: Fungus-specific IgEs were highly detectable in NPs of CRSwNP patients, and NPs comprised a major region of specific IgE production. Fungi may therefore play an important role in CRSwNP pathogenesis by inducing Th2 immune responses, including IgE synthesis.


Subject(s)
Antibodies, Fungal/immunology , Immunoglobulin E/immunology , Mycoses/immunology , Nasal Polyps/immunology , Rhinitis/immunology , Sinusitis/immunology , Case-Control Studies , Chronic Disease , Fungi , Humans , Mycoses/complications , Nasal Polyps/microbiology , Rhinitis/microbiology , Sinusitis/microbiology
3.
Acta Psychiatr Scand ; 134(1): 65-72, 2016 07.
Article in English | MEDLINE | ID: mdl-27028708

ABSTRACT

OBJECTIVE: Bright light therapy is widely used as the treatment of choice for seasonal affective disorder. Nonetheless, our understanding of the mechanisms of bright light is limited and it is important to investigate the mechanisms. The purpose of this study is to examine the hypothesis that bright light exposure may increase [(18) F]-fluorodeoxyglucose (FDG) uptake in olfactory bulb and/or hippocampus which may be associated neurogenesis in the human brain. METHOD: A randomized controlled trial comparing 5-day bright light exposure + environmental light (bright light exposure group) with environmental light alone (no intervention group) was performed for 55 participants in a university hospital. The uptake of [(18) F]FDG in olfactory bulb and hippocampus using FDG positron emission tomography was compared between two groups. RESULTS: There was a significant increase of uptake in both right and left olfactory bulb for bright light exposure group vs. no intervention group. After adjustment of log-transformed illuminance, there remained a significant increase of uptake in the right olfactory bulb. CONCLUSION: The present findings suggest a possibility that 5-day bright light exposure may increase [(18) F]FDG in the right olfactory bulb of the human brain, suggesting a possibility of neurogenesis. Further studies are warranted to directly confirm this possibility.


Subject(s)
Fluorodeoxyglucose F18/pharmacokinetics , Hippocampus/metabolism , Hippocampus/radiation effects , Olfactory Bulb/metabolism , Olfactory Bulb/radiation effects , Seasonal Affective Disorder/metabolism , Seasonal Affective Disorder/therapy , Adult , Female , Hippocampus/drug effects , Humans , Light , Male , Middle Aged , Olfactory Bulb/diagnostic imaging , Phototherapy/methods , Positron-Emission Tomography/methods , Radiopharmaceuticals/pharmacokinetics , Seasonal Affective Disorder/diagnostic imaging , Treatment Outcome , Young Adult
4.
Transpl Infect Dis ; 18(4): 611-6, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27237466

ABSTRACT

Disseminated infection by Hormographiella aspergillata is extremely rare and small intestine involvement has not been reported previously. A 51-year-old man with myelodysplastic syndrome developed pneumonia after cord blood cell transplantation. Fungal growth from the biopsied lung was identified as H. aspergillata by morphology and the gene analysis. Although antifungal agents including voriconazole and liposomal amphotericin B were administered, he died of disseminated H. aspergillata infection. We review the literature and discuss the treatment and prognosis.


Subject(s)
Agaricales/pathogenicity , Antifungal Agents/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Immunosuppression Therapy/adverse effects , Invasive Fungal Infections/microbiology , Rare Diseases/microbiology , Agaricales/genetics , Agaricales/isolation & purification , Antifungal Agents/administration & dosage , Brain/diagnostic imaging , Brain/pathology , Central Nervous System Fungal Infections/blood , Central Nervous System Fungal Infections/drug therapy , Central Nervous System Fungal Infections/etiology , Central Nervous System Fungal Infections/pathology , DNA, Fungal , Graft vs Host Disease/prevention & control , Humans , Immunosuppression Therapy/methods , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Intestinal Diseases/blood , Intestinal Diseases/drug therapy , Intestinal Diseases/etiology , Intestinal Diseases/pathology , Intestine, Small/pathology , Invasive Fungal Infections/blood , Invasive Fungal Infections/drug therapy , Lung Diseases, Fungal/blood , Lung Diseases, Fungal/drug therapy , Lung Diseases, Fungal/etiology , Lung Diseases, Fungal/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Myelodysplastic Syndromes/surgery , Neutropenia/drug therapy , Neutropenia/etiology , Neutropenia/microbiology , Rare Diseases/blood , Rare Diseases/drug therapy , Sequence Analysis, DNA , Tomography, X-Ray Computed , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , Transplantation, Homologous/adverse effects
5.
Pharmacopsychiatry ; 49(5): 182-185, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27111132

ABSTRACT

Introduction: Lamotrigine is one of several mood stabilizers and its effects for the treatment and prevention of depressive episodes, particularly in bipolar disorder, are generally accepted. Although the findings about a therapeutic window of lamotrigine are yet to be determined, it seems important to obtain information on individual pharmacokinetic peculiarities. This study was conducted to formulate the predictive model of plasma lamotrigine levels. Methods: Using the data of 47 patients whose lamotrigine levels, liver function, and renal function were measured, predictive models of lamotrigine levels were formulated by stepwise multiple regression analyses. The predictive power of the models was compared using another dataset of 25 patients. Results: Two models were created using stepwise multiple regression. The first model was: plasma lamotrigine level (µg/mL)=2.308+0.019×lamotrigine dose (mg/day). The second model was: plasma lamotrigine level (µg/mL)=0.08+0.024×lamotrigine dose (mg/day)+4.088×valproate combination (no=0, yes=1). The predictive power of the second model was better than that of the first model. Discussion: The present study proposes a prompt and relatively accurate equation to predict lamotrigine levels.


Subject(s)
Bipolar Disorder/blood , Excitatory Amino Acid Antagonists/blood , Triazines/blood , Adult , Antimanic Agents/therapeutic use , Bipolar Disorder/drug therapy , Excitatory Amino Acid Antagonists/therapeutic use , Female , Humans , Kidney/drug effects , Kidney/physiology , Lamotrigine , Liver/drug effects , Liver/physiology , Male , Middle Aged , Predictive Value of Tests , Regression Analysis , Triazines/therapeutic use , Valproic Acid/therapeutic use
6.
Clin Exp Allergy ; 44(3): 450-7, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24372664

ABSTRACT

BACKGROUND: Schizophyllum commune is one of the causative agents of basidiomycosis including disorders such as allergic bronchopulmonary mycosis, allergic fungal sinusitis, and mucoid impaction of bronchi, the incidence of those of which has been increasing. These mycoses are difficult to diagnose because only a limited number of diagnostic tools are currently available. The biggest problem is that no specific antigens of S. commune have been identified to enable serodiagnosis of the disease. OBJECTIVE: In this study, we attempted to identify a major antigen of S. commune to establish a reliable serodiagnostic method. METHODS: We used mass spectrometry to identify an antigen that reacted with the serum of a patient with allergic bronchopulmonary mycosis caused by S. commune. The protein was expressed in Escherichia coli, highly purified, and the patient sera IgG and IgE titres against the protein were determined by enzyme-linked immunosorbent assay. RESULTS: The protein identified as a major antigen of S. commune was named Sch c 1; it was a homolog of glucoamylase. The IgG and IgE titres against Sch c 1 in patient sera were significantly higher than those in healthy volunteer sera (P < 0.01). CONCLUSIONS AND CLINICAL RELEVANCE: Sch c 1 is recognized by the host immune system of patients as an antigen/allergen. The purified glucoamylase Sch c 1 is a promising candidate antigen for the serodiagnosis of S. commune-induced mycosis.


Subject(s)
Allergens/immunology , Antigens, Fungal/immunology , Glucan 1,4-alpha-Glucosidase/immunology , Mycoses/immunology , Schizophyllum/immunology , Allergens/chemistry , Amino Acid Sequence , Antibodies, Fungal/blood , Antibodies, Fungal/immunology , Antigens, Fungal/chemistry , Cross Reactions/immunology , Glucan 1,4-alpha-Glucosidase/chemistry , Humans , Immunoglobulin E/blood , Immunoglobulin E/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Molecular Sequence Data , Mycoses/blood , Pulmonary Aspergillosis/immunology , Schizophyllum/enzymology , Sequence Alignment
8.
Pharmacopsychiatry ; 47(7): 270, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25295550

ABSTRACT

Professors Grunze and Walden sent a letter associated with our article. In this letter, we reply to their comments.


Subject(s)
Excitatory Amino Acid Antagonists/therapeutic use , Mood Disorders/blood , Mood Disorders/drug therapy , Triazines/blood , Triazines/therapeutic use , Female , Humans , Male
9.
Pharmacopsychiatry ; 47(3): 111-4, 2014 May.
Article in English | MEDLINE | ID: mdl-24846086

ABSTRACT

INTRODUCTION: Lamotrigine is widely used for mood disorders including bipolar disorder and major depression, but its therapeutic levels have yet to be determined. This study was conducted to investigate the hypothesis that lamotrigine may have a therapeutic window for mood disorders. METHODS: 25 patients with mood disorders received lamotrigine for more than one year during which time plasma lamotrigine levels were measured at least once. Their mental state was retrospectively and regularly but blindly assessed using the Clinical Global Impression-Severity (CGI-S) scale. In order to investigate our hypothesis, we depicted the relationship between the last lamotrigine levels and the last CGI scores in 25 patients. If any, the potential therapeutic window was further investigated. RESULTS: The relationship between the last lamotrigine levels and the last CGI scores in the 25 patients indicated the presence of a therapeutic window of lamotrigine from 5 to 11 µg/mL. The repeated measures of ANOVA reached a significant tendency of the effects of lamotrigine levels within 5-11 µg/mL on better CGI-S scores, and the CGI-S scores at the last observation of the 15 patients whose lamotrigine levels were within 5-11 µg/mL were significantly better than those of 10 patients whose lamotrigine levels were not within 5-11 µg/mL. CONCLUSION: These findings suggest that lamotrigine may have a therapeutic window for patients with mood disorder from 5 to 11 µg/mL.


Subject(s)
Excitatory Amino Acid Antagonists/therapeutic use , Mood Disorders/blood , Mood Disorders/drug therapy , Triazines/blood , Triazines/therapeutic use , Adult , Aged , Analysis of Variance , Drug Monitoring , Excitatory Amino Acid Antagonists/blood , Female , Humans , Lamotrigine , Longitudinal Studies , Male , Middle Aged , Psychiatric Status Rating Scales , Retrospective Studies
11.
Eur J Clin Microbiol Infect Dis ; 32(3): 387-97, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23052987

ABSTRACT

The safety and efficacy profile of caspofungin and micafungin in Japanese patients with fungal infections were directly compared in this prospective, randomized, double-blind study. The proportion of patients who developed significant drug-related adverse event(s) (defined as a serious drug-related adverse event or a drug-related adverse event leading to study therapy discontinuation) was compared in 120 patients [caspofungin 50 mg, or 50 mg following a 70-mg loading dose on Day 1 (hereinafter, 70/50 mg) group: 60 patients; micafungin 150 mg: 60 patients]. The overall response rate was primarily evaluated in the per-protocol set (PPS) population. The proportion of patients who developed significant drug-related adverse events was 5.0 % (3/60) in the caspofungin group and 10.0 % (6/60) in the micafungin group [95 % confidence interval (CI) for the difference: -15.9 %, 5.2 %]. The favorable overall response in the PPS population for patients with esophageal candidiasis, invasive candidiasis, and chronic pulmonary aspergillosis including aspergilloma was 100.0 % (6/6), 100.0 % (3/3), and 46.7 % (14/30) in the caspofungin group, and 83.3 % (5/6), 100.0 % (1/1), and 42.4 % (14/33) in the micafungin group, respectively. In Japanese patients with Candida or Aspergillus infections, there was no statistical difference in the safety between caspofungin and micafungin. Consistent with other data on these two agents, the efficacy of caspofungin and micafungin was similar.


Subject(s)
Aspergillosis/drug therapy , Candidiasis/drug therapy , Echinocandins/administration & dosage , Echinocandins/adverse effects , Lipopeptides/administration & dosage , Lipopeptides/adverse effects , Aged , Aged, 80 and over , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects , Caspofungin , Double-Blind Method , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/pathology , Female , Humans , Japan , Male , Micafungin , Middle Aged , Prospective Studies , Treatment Outcome
13.
Transpl Infect Dis ; 14(1): 91-4, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21535337

ABSTRACT

Rhodotorula species have been increasingly recognized as emerging pathogens, particularly in immunocompromised patients. We herein report on a patient with myelodysplastic syndrome who developed fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor. He developed severe acute graft-versus-host disease requiring high-dose steroids, and had serially been administered fluconazole and micafungin for the prophylaxis of fungal infection. Although several cases of Rhodotorula infection after HSCT have been reported, all of them were recipients of autologous HSCT, not allogeneic HSCT. A review of all the reported cases of Rhodotorula infection after HSCT revealed that all patients had received fluconazole or echinocandins before the onset of infection. The findings suggest that Rhodotorula species could be causative yeasts, particularly in patients receiving fluconazole or echinocandins, both of which are inactive against the species.


Subject(s)
Fungemia/microbiology , Hematopoietic Stem Cell Transplantation/adverse effects , Mycoses/microbiology , Rhodotorula/isolation & purification , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Fungemia/drug therapy , Graft vs Host Disease/etiology , Humans , Male , Middle Aged , Mycoses/drug therapy , Myelodysplastic Syndromes/therapy , Rhodotorula/classification , Rhodotorula/genetics , Transplantation, Homologous/adverse effects , Unrelated Donors
14.
Asian J Pharm Sci ; 17(6): 938-948, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36600899

ABSTRACT

Currently commercial fixed-concomitant three agents have multiple problems such as multiple dosing administration, poor efficacy and side effects. Once-daily fixed-combination timolol-netarsudil-latanoprost ophthalmic solution (FC-TNL) has the ability to treat glaucoma by lowering the intraocular pressure (IOP) with great efficacy and improving patient compliance. However, the commercialized netarsudil dimesylate precipitated when the pH of the solution was above 5.4, or when maleic acid, the salt of commercial timolol maleate, was mixed with netarsudil dimesylate. Consequently, the homologous salt engineering strategy was used to make netarsudil dimesylate soluble in pH 4.8-5.2 solution by synthesizing timolol mesylate. Next, the morphology of timolol mesylate was observed by scanning electron microscopy, differential scanning calorimetry, thermogravimetric analysis, and powder X-ray diffraction. The prepared FC-TNL showed good stability during refrigeration storage. Additionally, FC-TNL exerted no influence on the intraocular penetration of each active compounds in the pharmacokinetic study. Importantly, once-daily FC-TNL exerted potent IOP-lowering effect and protective effect on retinal ganglion cells. The FC-TNL was stable, safe and effective, being a promising glaucoma therapeutic.

15.
Eur Surg Res ; 44(3-4): 159-69, 2010.
Article in English | MEDLINE | ID: mdl-20332642

ABSTRACT

PURPOSE: In severe acute pancreatitis (SAP), multiple organ dysfunction syndrome is a contributor to high mortality. We recently demonstrated that the serum interleukin (IL)-15 level is a predictor of the complications and mortality in clinical SAP. The aim was to investigate the role of IL-15 in experimental SAP. MATERIALS AND METHODS: SAP was induced by retrograde injection of 3 and 20% sodium deoxycholate (DCA) into biliopancreatic ducts in rats (DCA pancreatitis). Expressions of IL-15 were evaluated by Western blotting and immunohistochemical staining. Recombinant IL-15 protein was administered intraperitoneally, and the effects were investigated. RESULTS: Western blotting revealed the expressions of IL-15 in the pancreas, liver, lung and intestine in 3% DCA pancreatitis. Immunohistochemical staining showed the expression of IL-15 in the cytoplasm of each organ. In 3% DCA pancreatitis, administration of recombinant IL-15 protein attenuated the elevation of serum alanine aminotransferase (ALT) levels and improved the morphological change of the lung 18 h after the induction of SAP. Moreover, in 20% DCA pancreatitis, IL-15 improved the elevation of serum amylase and ALT levels 6 h after the induction. CONCLUSIONS: These results suggest that IL-15 is related to organ dysfunction during SAP, and that IL-15 functions as a protective factor against the organ injuries.


Subject(s)
Interleukin-15/metabolism , Pancreatitis/immunology , Alanine Transaminase/blood , Amylases/blood , Animals , Deoxycholic Acid/toxicity , Humans , Immunohistochemistry , Interleukin-15/therapeutic use , Intestine, Small/drug effects , Intestine, Small/microbiology , Intestine, Small/pathology , Lung Injury/drug therapy , Lung Injury/pathology , Male , Pancreatitis/chemically induced , Pancreatitis/drug therapy , Pancreatitis/metabolism , Rats , Rats, Wistar , Recombinant Proteins/therapeutic use , Tissue Distribution
16.
J Hosp Infect ; 2020 Apr 28.
Article in English | MEDLINE | ID: mdl-32360338

ABSTRACT

BACKGROUND: Invasive fusariosis (IF) is a frequently fatal disease as there are few antifungals to treat it, making the prevention of IF crucial. However, fusarium infections have not been as thoroughly studied as other common pathogenic fungi such as Aspergillus or Candida. AIM: To investigate the epidemiology of IF in patients with haematological diseases in Japan and to elucidate the infectious route of fusarium infection. METHODS: We retrospectively analysed 29 IF cases in patients with haematological diseases from 2009 to 2019 in Japan. To discover the infectious source of IF, we performed an indoor environment survey targeted at indoor air and drain outlets in medical institutions and residences using culture-based and metagenomic methods. Finally, we performed aerosol- and droplet-mediated dispersion studies. FINDINGS: The epidemiological study showed that the primary pathogen of IF was Fusarium solani species complex (FSSC), and the most common species was Fusarium petroliphilum. Most patients were likely to develop IF during hospitalization. A fusarium culture was positive in 26 of 72 drain samples. Few fusarium were detected from air samples; by contrast, 29 of 108 isolates from the drain outlets were identified as fusarium. Furthermore, similar results were obtained in the metagenomic analysis. Interestingly, species belonging to FSSC were isolated from indoor drain outlets, which was similar to those of the IF patients. In the droplet-mediated dispersion study, eight to 17 colonies of fusarium were isolated. CONCLUSION: Our study indicates that causative Fusarium spp. could inhabit drain outlets in hospitals or residences, and droplet-mediated fusarium dispersion is a potential cause of IF.

17.
J Clin Lab Anal ; 23(2): 139-43, 2009.
Article in English | MEDLINE | ID: mdl-19288448

ABSTRACT

The fungus Paracoccidioides brasiliensis is the pathogen of paracoccidioidomycosis (PCM), a systemic mycosis prevalent in Latin America. The loop-mediated isothermal amplification method (LAMP) was used in this study to detect the presence of P. brasiliensis in sputa samples from patients with chronic PCM, suspected PCM, and a negative control. The target P. brasiliensis gp43 gene was amplified in less than 4 hr in 11 of 18 sputa samples tested. The LAMP method had the advantage of speed and simplicity compared with the classic diagnostic methods such as the histopathological test or biological material culture and did not require sophisticated technical apparatus. It would be an important aid in cases where immediate treatment would mean patient survival, especially in immune-suppressed patients.


Subject(s)
Antigens, Fungal/genetics , Fungal Proteins/genetics , Glycoproteins/genetics , Nucleic Acid Amplification Techniques/methods , Paracoccidioides/isolation & purification , Paracoccidioidomycosis/diagnosis , Sputum/microbiology , Adult , Aged , Diagnostic Errors , Humans , Male , Middle Aged , Paracoccidioides/genetics , Sensitivity and Specificity
18.
J Fish Dis ; 32(10): 893-900, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19735347

ABSTRACT

This report describes Exophiala infection in cultured striped jack, Pseudocaranx dentex, in Japan in 2005. One hundred out of 35,000 fish died per day and mortalities continued for 1 month. Diseased fish showed swelling of the abdomen and kidney distension. Numerous septate hyphae, pale brown in colour, were seen in kidney in squash preparations. Histology revealed abundant fungal hyphae and conidia in gill, heart and kidney. Fungal hyphae were accompanied by cell necrosis and influx of inflammatory, mainly mononuclear cells. The fungus isolated from the diseased fish had septate hyphae, pale brown in colour and 1.8-3.0 microm in diameter. Conidiogenous cells were conspicuous annellides, short or cylindrical or fusiform in shape. Conidia were one-celled, ellipsoidal with smooth walls, accumulated in balls at the apices of annellides that tended to slide down, 1.5-2.0 microm in width and 3.0-5.0 microm in length. The fungus was classified into the genus Exophiala based on its morphology and as Exophiala xenobiotica based on the sequences of the ITS 1-5.8S-ITS 2 regions of rDNA. This is the first record of this fungus in a marine fish.


Subject(s)
Disease Outbreaks/veterinary , Exophiala/immunology , Fish Diseases/microbiology , Kidney Diseases/veterinary , Mycoses/veterinary , Perciformes , Animals , DNA, Fungal/chemistry , DNA, Fungal/genetics , DNA, Ribosomal Spacer/chemistry , DNA, Ribosomal Spacer/genetics , Exophiala/genetics , Exophiala/ultrastructure , Fish Diseases/epidemiology , Fish Diseases/immunology , Histocytochemistry/veterinary , Japan/epidemiology , Kidney Diseases/epidemiology , Kidney Diseases/immunology , Kidney Diseases/microbiology , Microscopy, Electron, Scanning/veterinary , Mycoses/epidemiology , Mycoses/microbiology , Phylogeny , Polymerase Chain Reaction/veterinary
19.
Lab Anim ; 43(4): 399-401, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19535395

ABSTRACT

Endotracheal intubation in mice is both a common and important technique. However, it is a difficult procedure because of the small orotracheal size and the success rate is variable. There have been many reports of refined techniques that facilitate intubation but only a few reports have proposed how to verify the proper placement of the endotracheal tube. We describe a novel, safe and reliable method to confirm endotracheal intubation in mice using an extension tube for intravenous infusion. One drop of water was instilled in the extension tube and connected to the end of the catheter used as an endotracheal tube. When the catheter was inserted correctly into the trachea, the water in the extension tube oscillated in synchrony with the movement of the mouse's thorax, indicating correct placement of the catheter. This method was simple, reliable and use materials that are routinely available. This method is helpful for experimental mouse models that require airway access.


Subject(s)
Intubation, Intratracheal/veterinary , Surgery, Veterinary/methods , Transillumination/instrumentation , Animals , Intubation, Intratracheal/instrumentation , Intubation, Intratracheal/methods , Mice , Models, Animal
20.
Transplant Proc ; 50(10): 3925-3927, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30577288

ABSTRACT

BACKGROUND: Azathioprine (AZA) is the drug recommended for the continuation of immunosuppressive treatment after renal transplant in women during pregnancy. CASE REPORT: A 37-year-old Japanese female developed agranulocytosis and severe alopecia after initiation of AZA (50 mg), used as an alternative to mycophenolate mofetil (MMF, 1000 mg) therapy in anticipation of a planned pregnancy. Within 4 days of the initiation of AZA therapy, the patient developed a high fever, leucopenia, and cranial alopecia. Genetic testing revealed a homozygous polymorphism of NUDT15 (rs116855232, NM_018283.3:c.415C>T: p.Arg139Cys), which has previously been identified as a risk factor for AZA-related complications in patients with inflammatory bowel disease. CONCLUSION: Genetic screening for NUDT15 could contribute to the prevention of serious adverse reactions to AZA and provide the opportunity for personalized medicine. Identification of a safe alternative to MMF during pregnancy after a renal transplant is a problem to be resolved in the future.


Subject(s)
Azathioprine/adverse effects , Immunosuppressive Agents/adverse effects , Kidney Transplantation , Pyrophosphatases/genetics , Adult , Agranulocytosis/chemically induced , Alopecia/chemically induced , Female , Graft Rejection/prevention & control , Homozygote , Humans , Kidney Transplantation/methods , Polymorphism, Single Nucleotide/genetics , Pregnancy , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL